Corient Private Wealth LP Acquires New Position in Encompass Health Corporation $EHC

Corient Private Wealth LP bought a new position in Encompass Health Corporation (NYSE:EHC) in the second quarter, Holdings Channel reports. The institutional investor bought 16,988 shares of the company’s stock, valued at approximately $1,717,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Encompass Health during the second quarter worth approximately $1,059,762,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Encompass Health by 3,059,159.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock valued at $402,640,000 after purchasing an additional 3,793,358 shares in the last quarter. Norges Bank bought a new position in shares of Encompass Health during the 4th quarter valued at $133,221,000. William Blair Investment Management LLC bought a new position in shares of Encompass Health during the 2nd quarter valued at $116,352,000. Finally, Price T Rowe Associates Inc. MD raised its position in Encompass Health by 24.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,805,413 shares of the company’s stock worth $510,047,000 after purchasing an additional 948,202 shares during the period. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Price Performance

Shares of Encompass Health stock opened at $122.79 on Friday. The company’s fifty day simple moving average is $114.92 and its two-hundred day simple moving average is $107.48. Encompass Health Corporation has a 12-month low of $92.77 and a 12-month high of $127.99. The firm has a market cap of $12.11 billion, a PE ratio of 20.00, a price-to-earnings-growth ratio of 2.45 and a beta of 0.75. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.76.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.40 earnings per share. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. As a group, equities analysts expect that Encompass Health Corporation will post 6.08 EPS for the current year.

Encompass Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Thursday, October 1st. This is a positive change from Encompass Health’s previous quarterly dividend of $0.19. Encompass Health’s dividend payout ratio is currently 12.38%.

Insider Activity at Encompass Health

In other Encompass Health news, EVP John Darby sold 4,858 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $121.09, for a total value of $588,255.22. Following the completion of the sale, the executive vice president owned 75,041 shares in the company, valued at approximately $9,086,714.69. This trade represents a 6.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Mark Tarr sold 173,148 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $125.47, for a total value of $21,724,879.56. Following the transaction, the chief executive officer directly owned 267,814 shares in the company, valued at $33,602,622.58. This trade represents a 39.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 186,912 shares of company stock valued at $23,434,845. Company insiders own 1.80% of the company’s stock.

Wall Street Analysts Forecast Growth

EHC has been the subject of several recent research reports. UBS Group boosted their price target on shares of Encompass Health from $150.00 to $155.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Weiss Ratings upgraded Encompass Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Leerink Partners set a $152.00 target price on Encompass Health in a research note on Friday, May 22nd. Truist Financial increased their target price on Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Barclays raised their price target on Encompass Health from $140.00 to $144.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $148.71.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.